Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for ...

Novo Nordisk says it's now cutting its annual outlook - seeing sales growth, at constant exchange rates, between 13% and 21%, vs. its previous forecast of 16% to 24%, and operating profit growth ...

Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later ...

Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.

The U.S. stock market continued to rebound from a period of volatility for the second straight week, with the S&P 500 closing ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

CVS Health Corp. reported a strong start to 2025, with first-quarter revenue climbing 7%, driven by growth across all ...